Today: 14 May 2026
Nebius (NBIS) stock jumps on report of 800MW Kansas City-area data center plan
12 January 2026
2 mins read

Nebius (NBIS) stock jumps on report of 800MW Kansas City-area data center plan

New York, January 12, 2026, 14:05 EST — Regular session

  • Nebius shares climbed roughly 10% during Monday’s afternoon session
  • A report detailed plans for an 800-megawatt AI data center campus close to Kansas City
  • Investors are focused on local approvals and how quickly power capacity is coming online

Nebius Group N.V. shares surged roughly 10% Monday following reports that the AI infrastructure company plans to build an 800-megawatt data center campus near Kansas City, Missouri. The stock climbed 10.2% to $107.87 in afternoon trading, up from Friday’s close of $97.93.

This shift comes in a market where power remains the bottleneck for artificial intelligence. Chips are available, but snapping up an additional 800 megawatts of electricity—and the necessary grid hookups—is far from simple.

Nebius has been locking down major, long-term deals and then hustling to secure the infrastructure—land, power, and facilities—needed to support them. “We should be ready (for when) the winter will come,” co-founder Roman Chernin told Reuters in December, emphasizing that the company is focusing on high-margin services to weather any downturn. Reuters

Data Center Dynamics reports the proposed site is in Independence, Missouri, where the city envisions a 2.5 million-square-foot campus at Eastgate Commerce Center, potentially stretching across 10 buildings. The project demands at least 800 megawatts of power. Plans include a new privately funded power facility built in phases — starting with a 250-megawatt segment aimed for completion by October 2027, followed by a larger expansion by late 2029.

Independence’s project FAQ reveals plans for a campus spanning up to 10 buildings across about 400 acres, with construction slated to start in early 2026. City officials anticipate tens of millions in tax revenue by 2028. The estimate for land acquisition and site/building improvements comes to $6.6 billion.

The local calendar shows a Nebius open house scheduled for Monday, followed by a Planning Commission meeting on Tuesday. Traders are watching closely, as upcoming headlines will probably focus on zoning, permits, and whether the project moves forward smoothly.

Nebius has pitched itself as the middle ground between hyperscalers—the massive cloud providers—and customers hunting for rare, AI-ready computing power. If the Kansas City-area project goes ahead, it would clearly show Nebius’s readiness to invest heavily in securing large-scale U.S. capacity.

The downside scenario is well known: these projects stretch over years, and delays are common. Nebius has poured money into GPUs—the chips powering AI training and operations—along with land and energy. Reuters reported that the company’s capital expenditures jumped sharply in 2025, even as it recorded quarterly losses.

Another risk lies in the power build-out—it’s a project within the larger project. Should the generation plan or grid connections slip, the data center schedule could quickly shift from a growth opportunity into a cash drain.

Investors are now eyeing Independence City Hall, where the Planning Commission will review the project on Jan. 13. The proposal is slated for the full City Council agenda a week later, on Jan. 20, according to local outlet KSHB.

Stock Market Today

  • Nurix Therapeutics Stock: Is Its Premium 23.3x Price-to-Sales Multiple Justified?
    May 14, 2026, 9:02 AM EDT. Nurix Therapeutics (NRIX) shares rose 1.38% to $16.18 amid mixed recent performance, down 10% year to date but up nearly 69% over one year. The stock trades at a high price-to-sales (P/S) multiple of 23.3x, well above the US biotech average of 9.7x. This premium reflects strong analyst revenue growth forecasts of 42.2% annually, outpacing the broader market. However, Nurix remains loss-making with $295 million in ongoing losses and a $1.65 billion market cap, making it vulnerable to clinical setbacks. Investors should weigh the high growth potential against risks in this early-stage biotech before assuming the premium valuation is sustainable.

Latest articles

Apple Backs Google in EU AI Fight as iPhone Rules Loom

Apple Backs Google in EU AI Fight as iPhone Rules Loom

14 May 2026
Apple warned the European Commission that proposed EU rules forcing Google’s Android to open core features to rival AI assistants could endanger privacy, security, and device performance. The Commission’s feedback period closed Wednesday, with a final decision expected by July 27. Apple argued the measures could set a precedent for its own platforms. Google also opposes the plan, calling it an “unwarranted intervention.”
Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

14 May 2026
Precigen shares jumped 14.1% in early trading after first-quarter revenue reached $23.3 million, beating estimates, and net loss narrowed to $7.9 million from $54.2 million a year earlier. Papzimeos, its new RRP therapy, generated $21.6 million in net product revenue. The company ended March with $56.7 million in cash and expects current funds and Papzimeos sales to last through 2026.
POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

14 May 2026
POET Technologies signed a supply and joint-development agreement with Lumilens, including a $50 million initial order for optical engines used in AI data-center networks. The companies said cumulative purchases could exceed $500 million over five years. POET shares rose 16% after the news. First engineering samples are expected in late 2026, with production targeted for 2027.
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy
Previous Story

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

CompoSecure stock drops 8% as Husky deal closes; GPGI ticker switch set for Jan. 23
Next Story

CompoSecure stock drops 8% as Husky deal closes; GPGI ticker switch set for Jan. 23

Go toTop